Skip to main content

Table 1 Baseline clinical, echocardiographic, and laboratory data of the study population

From: Response of circulating heat shock protein 70 and anti-heat shock protein 70 antibodies to catheter ablation of atrial fibrillation

  AF population Controls
  n=67 n=34
Age (years) 59 ± 11 59 ± 11
Males (%) 66 66
Paroxysmal AF (%) 58 0
Lone AF (%) 66 -
AF history (months) 72 ± 60 -
LVEF (%) 60 ± 9 62 ± 8
LAD (mm) 43 ± 6 41 ± 5
anti-HSP70 antibodies (μg/ml) 48 [36 – 72] 40 [32 – 70]
HSP70 (ng/ml)* 0 [0 – 0] 0 [0 – 0]
hs-CRP (μg/ml) 2.07 ± 1.10 1.80 ± 0.85
  1. HSP70 and anti-HSP70 antibodies are presented as median [IQR].
  2. * detectable in 21% of AF patients and 19% of controls.
  3. LAD = left atrial diameter, LVEF = left ventricular ejection fraction.